Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID M BEAR

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1689643645
CMS profile
211881
Location
PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$59,031.55

275 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $16,919.11 28
Biohaven Pharmaceuticals, Inc. $15,528.54 25
Lilly USA, LLC $10,021.16 21
Allergan, Inc. $4,718.52 10
Teva Pharmaceuticals USA, Inc. $4,553.81 14
Lundbeck LLC $3,235.22 8
Amgen Inc. $1,506.98 12
Novartis Pharmaceuticals Corporation $454.94 35
JAZZ PHARMACEUTICALS INC. $262.12 18
SK Life Science, Inc. $170.25 11
Genentech USA, Inc. $127.52 8
Biogen, Inc. $124.48 8
GENZYME CORPORATION $90.39 5
Acorda Therapeutics, Inc $86.77 4
UCB, Inc. $85.42 4
Celgene Corporation $74.23 5
CSL Behring $72.20 2
Eisai Inc. $71.62 4
Amneal Pharmaceuticals LLC $63.32 3
Horizon Therapeutics plc $61.28 3
Sunovion Pharmaceuticals Inc. $57.33 4
Kyowa Kirin, Inc. $57.00 3
Philips Electronics North America Corporation $52.85 1
E.R. Squibb & Sons, L.L.C. $50.56 3
PFIZER INC. $43.95 3
CATALYST PHARMACEUTICALS, INC. $34.28 2
AstraZeneca Pharmaceuticals LP $33.56 2
Neurocrine Biosciences, Inc. $32.91 2
UPSHER-SMITH LABORATORIES LLC $32.65 2
Greenwich Biosciences, Inc. $32.57 2
Supernus Pharmaceuticals, Inc. $32.05 2
Alnylam Pharmaceuticals Inc. $31.62 2
Merck Sharp & Dohme Corporation $29.94 2
Xeris Pharmaceuticals, Inc. $29.45 2
MITSUBISHI TANABE PHARMA AMERICA, INC. $29.43 2
Takeda Pharmaceuticals U.S.A., Inc. $27.88 2
Currax Pharmaceuticals LLC $26.33 2
Grifols USA, LLC $23.80 1
LivaNova USA, Inc. $23.09 1
Akcea Therapeutics, Inc. $18.59 1
ACADIA Pharmaceuticals Inc $18.00 1
GE HEALTHCARE $17.63 1
BOSTON SCIENTIFIC CORPORATION $17.45 1
Mallinckrodt Hospital Products Inc. $17.21 1
Adamas Pharmaceuticals, Inc. $16.89 1
ARBOR PHARMACEUTICALS, INC. $16.65 1

Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID M BEAR

NPI 1689643645 · CMS profile ID 211881

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689643645?year=2021&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID M BEAR, NPI 1689643645, CMS profile ID 211881. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689643645?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID M BEAR, NPI 1689643645, CMS profile ID 211881. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689643645?year=2021&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID M BEAR, NPI 1689643645, CMS profile ID 211881, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–275 of 275 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1689643645?year=2021&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

275 matching records · $59,031.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 275 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–275 of 275.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $10.7302/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603707 CMS
Teva Pharmaceuticals USA, Inc. $1,680.0002/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839507793 CMS
Allergan, Inc. $1,440.0002/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792703147 CMS
AbbVie Inc. $12.6101/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794013145 CMS
Novartis Pharmaceuticals Corporation $15.3001/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603701 CMS
Amgen Inc. $19.0201/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825257627 CMS
Biogen, Inc. $16.4601/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827831575 CMS
Amgen Inc. $5.1601/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825257631 CMS
E.R. Squibb & Sons, L.L.C. $12.4101/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783664755 CMS
SK Life Science, Inc. $9.0301/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826824911 CMS
Novartis Pharmaceuticals Corporation $4.8201/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603705 CMS
Amneal Pharmaceuticals LLC $17.1701/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829645981 CMS
Biohaven Pharmaceuticals, Inc. $8.0001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852420735 CMS
Allergan, Inc. $1,440.0001/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792703145 CMS
Novartis Pharmaceuticals Corporation $17.4501/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603703 CMS
E.R. Squibb & Sons, L.L.C. $22.1901/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783664749 CMS
Lilly USA, LLC $750.0001/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819051577 CMS
Novartis Pharmaceuticals Corporation $20.2401/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603693 CMS
UPSHER-SMITH LABORATORIES LLC $21.5801/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834696785 CMS
Allergan, Inc. $1,750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792703143 CMS
Biogen, Inc. $16.8801/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827831577 CMS
Novartis Pharmaceuticals Corporation $13.4301/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603697 CMS
Novartis Pharmaceuticals Corporation $14.2601/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603699 CMS
Novartis Pharmaceuticals Corporation $7.2201/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812603695 CMS
SK Life Science, Inc. $12.3201/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826824905 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,672.87 277
PY2020 $70,847.13 318
PY2021 $59,031.55 275
PY2022 $67,086.92 293
PY2023 $37,886.67 297
PY2024 $95,809.13 332
PY2025 $139,461.82 324

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $27,100.00 8
PY2025 Principal investigator $1,784,588.49 21
PY2024 Recipient $71,256.43 5
PY2024 Principal investigator $2,611,551.51 15
PY2023 Recipient $13,837.50 3
PY2023 Principal investigator $2,487,668.88 17
PY2022 Recipient $32,185.00 4
PY2022 Principal investigator $1,653,045.59 11
PY2021 Recipient $10,622.83 8
PY2021 Principal investigator $846,711.49 21
PY2020 Recipient $26,338.95 4
PY2020 Principal investigator $132,181.16 5
PY2019 Principal investigator $38,255.67 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Ipsen Innovation $500.00 12/24/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291324
Recipient Ipsen Innovation $2,000.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291312
Recipient Ipsen Innovation $3,000.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291314
Recipient Ipsen Innovation $1,500.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291316
Recipient Ipsen Innovation $12,000.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291318
Recipient Ipsen Innovation $1,500.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291320
Recipient Ipsen Innovation $1,100.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291322
Recipient Ipsen Innovation $5,500.00 12/19/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291326
Principal investigator 1 Novartis Pharmaceuticals Corporation $50.00 12/01/2025 Non-covered Recipient Entity
EMERALD COAST CENTER FOR NEUROLOGICAL DISORDERS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304137
Principal investigator 1 Ipsen Innovation $126.00 10/03/2025 Non-covered Recipient Entity
Emerald Coast Center For Neurological Disorders
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288540
Principal investigator 1 Ipsen Innovation $695.00 09/26/2025 Non-covered Recipient Entity
Emerald Coast Center For Neurological Disorders
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288536
Principal investigator 1 Ipsen Innovation $2,790.00 09/26/2025 Non-covered Recipient Entity
Emerald Coast Center For Neurological Disorders
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288538
Principal investigator 1 Eli Lilly and Company $2,439.00 07/10/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 1187880583
Principal investigator 1 Eli Lilly and Company $22,283.00 06/23/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY No dispute reported 06/30/2026 1187880207
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $47,604.75 02/19/2025 Non-covered Recipient Entity
Synergy Clinical Research Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235993385
Principal investigator 1 Novartis Pharmaceuticals Corporation $411,632.44 02/19/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190311825
Principal investigator 1 Eli Lilly and Company $52.05 02/12/2025 Non-covered Recipient Entity
INLAND RHEUMATOLOGY CLINICAL TRIALS INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883992
Principal investigator 1 Eli Lilly and Company $108,960.00 01/28/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187879919
Principal investigator 1 Eli Lilly and Company $536,774.00 01/28/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187880581
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,930.00 01/28/2025 Non-covered Recipient Entity
SYNERGY CLINICAL RESEARCH LLC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305593
Principal investigator 1 Eli Lilly and Company $786.83 01/27/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187880799
Principal investigator 1 Eli Lilly and Company $2,396.14 01/27/2025 Non-covered Recipient Entity
INLAND RHEUMATOLOGY CLINICAL TRIALS INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883536
Principal investigator 1 Eli Lilly and Company $117,410.00 01/17/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187883328
Principal investigator 1 Eli Lilly and Company $18,291.38 01/09/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881234
Principal investigator 1 Eli Lilly and Company $265,252.00 01/07/2025 Non-covered Recipient Entity
EMERALD COAST NEUROLOGY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881712
Principal investigator 1 Novartis Pharmaceuticals Corporation $47,827.25 01/07/2025 Non-covered Recipient Entity
EMERALD COAST CENTER FOR NEUROLOGICAL DISORDERS
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190313245
Principal investigator 1 Eli Lilly and Company $8,476.57 01/06/2025 Non-covered Recipient Entity
INLAND RHEUMATOLOGY CLINICAL TRIALS INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187881804
Principal investigator 1 Sage Therapeutics, LLC $18,025.00 01/06/2025 Non-covered Recipient Entity
SYNERGY CLINICAL RESEARCH LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 1206580288
Principal investigator 1 Novartis Pharmaceuticals Corporation $155,787.08 01/01/2025 Non-covered Recipient Entity
EMERALD COAST CENTER FOR NEUROLOGICAL DISORDERS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304139